Navigation Links
CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies
Date:4/3/2008

-Company Joins Supplier Base Offering Broad Array of Healthcare Products to

Patients with Immune Deficiency and Bleeding Disorders

OTTAWA, April 3, 2008 /PRNewswire/ -- CSL Behring Canada, Inc. today announced that Canadian Blood Services, and Hema-Quebec, have each awarded the company contracts to supply Helixate(R) FS (Antihemophilic Factor [Recombinant]), Humate(R) P (Antihemophilic factor / von Willebrand Factor Complex [Human], Dried, Pasteurized), Privigen (Immune Globulin Intravenous [Human]), Vivaglobin(R) (Immune Globulin Subcutaneous [Human]) and other plasma-derived products. These products are used for the treatment of conditions such as hemophilia, von Willebrand Disease, primary immunodeficiency as well as other serious conditions.

The contracts call for CSL Behring to supply the above mentioned life-saving therapies over a period of at least five years, and to provide toll manufacturing services to Canadian Blood Services for the fractionation of Canadian plasma. In addition, with this agreement, CSL Behring will become the main supplier of bleeding disorder treatments in the province of Quebec.

CSL Behring currently maintains a portfolio of 23 different products, which it develops, manufactures, and distributes to the global healthcare community. The company also offers comprehensive consumer support, research and education support, disease awareness campaigns and other initiatives to ensure that patients receive proper diagnoses and treatment interventions.

"We at CSL Behring in Canada are quite pleased with the awards," said Dr. Heinz Neuhaus, General Manager of CSL Behring Canada. "Our company has made significant investments in becoming a reliable partner for both Canadian Blood Services and Hema-Quebec so that we can expand our product offering to Canadian patients in need. It is gratifying to be recognized with a supply agreement that allows us to strengthen even further our commitment to saving and i
'/>"/>

SOURCE CSL Behring
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. CSL Behring Expands Into Middle East Market with Haemate(R) P
2. Siemens Completes Acquisition of Dade Behring
3. Siemens Receives EU Antitrust Clearance for Acquisition of Dade Behring
4. AMDL Signs Exclusive Licensing Agreement for Human Papilloma Virus Diagnostic Test Kit in Certain Asian Countries
5. Pharsight Signs Two New DMX(R) License Customers
6. Siemens Signs Multi-Year Agreement With Cleveland Clinic to Deploy Enterprise-Wide Cardiology PACS
7. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany
8. Cardiac Science Signs Letter of Intent With Misys Healthcare Systems to Connect With Their EMR Systems
9. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France
10. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
11. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...BOSTON,Nov.25/PRNewswire/--BiotechfirmReplikinsLtd...918pandemicthroughtheprediction,outbreak,andprogre...chemicalanalysisofthevirus.Thenewdatashowsthatthel...speakof3.7(s.d.4.5)duringthevirus,scurrentoutbreak...ekof2.0(s.d.0.1).TheH1N1virus,infectivitycount,how...
(Date:11/25/2009)...NEWYORK,Nov.25/PRNewswire/--Reportlinker.comannoun...alogue: ,, BrazilBioethanolMarketAnalysisandFo...p0165503/Brazil-Bioethanol-Market-Analysis-and-For...nalysisandForecaststo2013 ,, Summary ,, Th...obalbioethanolmarketandtheBrazilbioethanolmarketin...
(Date:11/24/2009)... The New York investment bank KTA...NEU) has agreed an AU$6.7 mil convertible note pri... The private placement was arranged by KTA Capital.... , New York (PRWEB) Nove...nt bank KTA Capital, LLC ("KTA Capital")...
(Date:11/24/2009)... Health care employment grew by... only one to show consistent growth during the U.S...als remain in trouble, and health systems are comi...nel, instead of just administrators. , ...care employment continued growing in October despi...
Breaking Biology Technology:Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4
... BOSTON, Jan. 15 PAREXEL International Corporatio...tical services organization, announced today it ha...ident and Chief Information Officer (CIO). Ms. Hop...mation technology (IT) initiatives and integrating... global basis. , , Prior to joining PAREXEL, Ms. ...
... ST. LOUIS, Jan. 14 As the latest step in its..., Monsanto Company,(NYSE: MON ) today announced ...increase in the quarterly dividend on its common s...are. The dividend is payable on April 24, 2009 to,...we have often said, when farmers succeed we succee...
... LAVAL, QC, Jan. 14 /PRNewswire-FirstCall/ - BioSy...veloping biotherapeutic thermogels for regenerativ...enrolment next month for the Canadian-European piv...Gel(R). To date, the Company has enrolled more tha...l be permitted to enrol additional subjects until ...
Other Biology Technology:PAREXEL Appoints Josephine Hoppe to Chief Information Officer 2PAREXEL Appoints Josephine Hoppe to Chief Information Officer 3PAREXEL Appoints Josephine Hoppe to Chief Information Officer 4Monsanto Board Approves 10 Percent Dividend Increase 2BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009 2BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009 3BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009 4
(Date:11/25/2009)... may be used to boost resistance to, or slow, the ... Medicine researchers report in a study published .... , Parkinson,s disease is caused by a degenerat... known as the substantia nigra, which is responsib... dopamine in late-stage Parkinson,s causes symptom...
(Date:11/25/2009)... Research Laboratory in the University of Haifa,s ...gious Johnson & Johnson Focused Funding grant for ...age in Parkinson,s disease. The award, which is gr...tion and excellence in science, was announced in 2...t an event at the Hyatt Regency Hotel in New Jerse...
(Date:11/25/2009)...ors recently received funding from the National Sc...cial to understanding the environment. The three g...ssistant professor in the Department of Biological...ate research projects. , His first project, titl...unctions from the Leaf to the Landscape," will exa...
Breaking Biology News(10 mins):Hormone ghrelin can boost resistance to Parkinson's disease 2Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Kent State University professors focus research on the environment with grants totaling $890,000 2New Nominee for WHO Regional Director for Europe 57339 1New Nominee for WHO Regional Director for Europe 57339 2Video 3A NFL Season Kicks Off With Campaign to Know Your Stats About Prostate Cancer 57336 1Video 3A NFL Season Kicks Off With Campaign to Know Your Stats About Prostate Cancer 57336 2Video 3A NFL Season Kicks Off With Campaign to Know Your Stats About Prostate Cancer 57336 3Video 3A NFL Season Kicks Off With Campaign to Know Your Stats About Prostate Cancer 57336 4GenVec Receives NASDAQ Notice of Minimum Bid Price Non Compliance 57333 1GenVec Receives NASDAQ Notice of Minimum Bid Price Non Compliance 57333 2GenVec Receives NASDAQ Notice of Minimum Bid Price Non Compliance 57333 3
...sts have demonstrated a new way to assess the pote...--a technique that could also be used to monitor a...isticated, noninvasive medical imaging tools. Scie...en National Laboratory, whose findings are reporte...Medicine,s Journal of Nuclear Medicine, used posit...
...s newest polymer innovation, the first DuPont poly...ognized by the China State Intellectual Property O... Visionary Innovation" at a recent award ceremony....ive the 2005 "New Technologies in Renewable Materi...d Environmental Conference, sponsored by the Socie...
...e sclerosis (MS) can be an unpredictable disease. ...healthy nerve cells and disrupts normal nerve sign...s—including tingling, paralysis, pain, fatigue, an...in combination, sporadically or persistently. Alth...-ups are common in the majority of patients. , MS...
Other Biology News:PET/MRI scans may help unravel mechanisms of prenatal drug damage 2PET/MRI scans may help unravel mechanisms of prenatal drug damage 3PET/MRI scans may help unravel mechanisms of prenatal drug damage 4DuPont's first biologically derived polymer receives global recognition 2Gene Signatures Predict Interferon Response For Multiple Sclerosis Patients 2
Customized Competent E. coli. from Molecular Cloning Laboratories (MCLAB)
Fluorescent Standards Red Standard from Invitrogen
X-Gal from GE Healthcare, formerly Amersham Biosciences
Mouse Anti-Oligodendrocyte Marker O1 Monoclonal Antibody, Unconjugated, Clone O1 from R&D Systems
Biology Products: